Arginine-degrading--enzyme therapy is beneficial for the treatment of cancers lacking the enzyme needed for arginine synthesis (argininosuccinate synthetase 1), according to a new report. With few ...
A plasma miRNA signature classifier identifies PD-L1 ≥ 50% NSCLC nonresponders to immune checkpoint inhibitors. A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Arginine deprivation with pegylated arginine deiminase may improve PFS and prolong life expectancy in patients with argininosuccinate synthetase 1–deficient malignant pleural mesothelioma, according ...
Scientists from the University of California, San Diego (UCSD) report that more than 90% of all bladder cancers are deficient in argininosuccinate synthetase 1 (ASS1), an enzyme necessary for arginine ...
HealthDay News — Loss of argininosuccinate synthetase 1 (ASS1), a key enzyme for arginine synthesis, occurs in invasive bladder cancer, according to a study published online in The American Journal of ...
HealthDay News — Loss of argininosuccinate synthetase 1 (ASS1), a key enzyme for arginine synthesis, occurs in invasive bladder cancer, according to a study published online in The American Journal of ...
Proceedings of the National Academy of Sciences of the United States of America, Vol. 57, No. 3 (Mar. 15, 1967), pp. 829-834 (6 pages) ...
Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial ...
Philadelphia, PA, December 12, 2016 - With few treatment options available to patients with advanced bladder cancer, investigators are looking for novel molecular targets. In a study published in The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback